Related Experiment Video
Updated: Dec 17, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Current Perspectives of Anticoagulation in Patients With COVID-19
Elizabeth M Gavioli1, Gabriela Sikorska1, Ammy Man1
1Division of Pharmacy, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Brooklyn, NY; and.
Insights
Patients with COVID-19 frequently experience thromboembolism and myocardial injury. Low-molecular-weight heparin may improve outcomes by reducing coagulation and inflammation, warranting consideration for thromboprophylaxis.
Area of Science:
- Cardiology
- Infectious Diseases
- Hematology
Background:
- COVID-19 is associated with a high incidence of thromboembolic events and myocardial injury.
- Coagulation and inflammation markers are often elevated in patients with COVID-19.
Purpose of the Study:
- To evaluate the role of low-molecular-weight heparin in managing COVID-19 associated coagulopathy.
- To provide recommendations for thromboprophylaxis and anticoagulation in hospitalized COVID-19 patients.
Main Methods:
- Observational analysis of clinical data from COVID-19 patients.
- Review of existing literature on anticoagulation in COVID-19.
Main Results:
- Low-molecular-weight heparin demonstrated an association with improved prognosis in COVID-19 patients.
- Low-molecular-weight heparin showed potential in reducing key coagulation and inflammation markers.
Conclusions:
- Hospitalized COVID-19 patients should receive thromboprophylaxis.
- Consideration for full therapeutic anticoagulation or tissue plasminogen activator is advised for high-risk or mechanically ventilated patients.
- Extended thromboprophylaxis at discharge may benefit high-risk individuals. Clinical judgment is crucial for balancing anticoagulation benefits against bleeding risks.
Abstract:
Thromboembolism and myocardial injury is common in patients with COVID-19. Low-molecular-weight heparin appears to be associated with a good prognosis in patients with COVID-19 and has the ability to reduce coagulation and inflammation markers. Hospitalized patients with COVID-19 should be placed on thromboprophylaxis with the option of full therapeutic anticoagulation or tissue plasminogen activator in high-risk or mechanically ventilated patients. Thromboprophylaxis should also be considered at hospital discharge for high-risk patients. Clinical judgment should be used to evaluate the bleeding and safety risk of anticoagulation in patients with COVID-19 without confirmed data.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism III: Nursing Management

